Could Dividend Champions BAE Systems plc, Vodafone Group Plc And AstraZeneca Also Grow By 50%?

Can Vodafone Group Plc (LON: VOD), AstraZeneca Plc (LON: AZN) and BAE Systems Plc (LON: BA) break the mould to provide income and growth?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares paying high dividends are normally thought of as low-growth businesses, but could BAE Systems (LSE: BA), Vodafone (LSE: VOD) and AstraZeneca (LSE: AZN) reward shareholders with dividends paying over 4% and appreciate in value by 50% or more?

Winning bet?

BAE shareholders will welcome with open arms the increasing defence budgets in the UK, US, and Saudi Arabia, which together account for over 75% of sales. Due to these increased budgets, BAE may finally reverse five straight years of declining revenues when full-year results are announced next week. During this rebuilding phase management did well to cut costs and increase margins, which allowed earnings per share to remain level from 2010 to 2015 even as revenue fell 25%.

With major business lines much more profitable than they were prior to 2010 and year-on-year revenue finally due to increase, BAE shares could be in for significant upward rerating. Trading at a forward price/earnings multiple of 11.7, there’s room for the shares to grow to reach the levels of major US competitors Boeing and Lockheed Martin, which trade at 14 and 18 times earnings, respectively. This growth potential may not reach a full 50% over the medium term, but with a healthy 4.1% yielding dividend and better days ahead I believe BAE could be a winning bet for income investors.

One to watch

Vodafone’s £20bn infrastructure investment programme, Project Spring, is finally coming to a close this year and has already begun to bear fruit for the mobile phone operator. 4G coverage has expanded from 32% to 80% of Europeans, opening up wide swathes of the continent to Vodafone’s highly profitable data packages.

Analysts are forecasting the possibility of 5% annual organic growth over the next five years. When combined with substantially lower capital expenditure, this is forecast to increase earnings by 19% next year alone. Furthermore, the 5.3% yielding dividend is now covered by earnings and holds the potential to rise alongside profits over the medium term. The bad news for intrigued investors is that much of this growth is baked into share prices already as they’re trading at 34 times projected 2017 earnings. Given current valuations, I don’t foresee the shares increasing in value by 50% over the medium term although Vodafone is still a share to watch.

Patent problems

Drug maker AstraZeneca was knocked back last week on poor guidance for 2016 after blockbuster cholesterol drug Crestor’s patent expired. With heartburn treatment Nexium losing its own patent later this year, AstraZeneca was forced to go on a $10bn buying spree last year to restock its drug pipeline. While the long-term prospects may be very good for AstraZeneca, as management is increasing R&D spending as well as M&A, I believe there will be further pain in the short term for prices.

It’s the nature of the pharmaceuticals industry that drugs take many years to develop before coming to market, and it could be years before AstraZeneca finds a replacement for Nexium and Crestor, which provided more than 35% of revenues last year. Share prices have been mostly flat for the past two years, allowing the P/E ratio to settle at a relatively attractive 15 times forward earnings. Shares may not skyrocket 50% anytime soon, but offer a 4.2% yield and are worth following over the next few years as more drugs go to trial.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ian Pierce has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »